LAW
Tenpoint Therapeutics Announces Breakthrough Phase 3 Results for Presbyopia Treatment Following Merger with Visus
Tenpoint Therapeutics, Visus merger, Phase 3 trial, presbyopia treatment, BRIMOCHOL PF, vision drug, ophthalmic therapeutics
LB-102 Shows Promise as Potential First-in-Class Benzamide Antipsychotic for Schizophrenia
LB-102, schizophrenia, Phase 2 trial, benzamide antipsychotic, efficacy, safety
LB-102 Shows Promise as Potential First-in-Class Benzamide Antipsychotic for Schizophrenia in US
LB-102, schizophrenia, Phase 2 trial, benzamide antipsychotic, efficacy, safety
Oculis’ Novel Peptidomimetic OCS-05 Shows Promising Results in Phase 2 Trial for Acute Optic Neuritis
Oculis, OCS-05, Peptidomimetic, Acute Optic Neuritis, Neuroprotective Therapy, Phase 2 Trial, ACUITY Trial
Neumora’s Navacaprant Fails to Meet Expectations in First Phase 3 Trial for Major Depressive Disorder
Neumora Therapeutics, Navacaprant, Major Depressive Disorder, Phase 3 Trial, KOASTAL-1 Study
Pfizer Terminates Development of Sangamo’s Hemophilia A Gene Therapy, Returning Full Rights to Sangamo
Pfizer, Sangamo Therapeutics, Hemophilia A, Gene Therapy, Giroctocogene Fitelparvovec, Phase 3 AFFINE Trial
CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target
CagriSema, Weight Loss, Phase 3 REDEFINE 1 Trial, Obesity Treatment, Novo Nordisk, Semaglutide, Cagrilintide
Relmada Therapeutics Explores Strategic Alternatives Following Discontinuation of Two Phase 3 Trials
Relmada Therapeutics, Phase 3 trials, Strategic alternatives, REL-1017, REL-P11, Central nervous system diseases, Metabolic disorders
Relmada Therapeutics Reassesses Strategy Following Discontinuation of Two Phase 3 Trials for REL-1017
Relmada Therapeutics, REL-1017, Phase 3 trials, Major Depressive Disorder (MDD), strategic options, clinical trials, drug development
Merck’s Investigational ADC Zilovertamab Vedotin Enters Phase 3 with 100% Complete Response Rate in DLBCL Patients
Zilovertamab Vedotin, Antibody-Drug Conjugate (ADC), Diffuse Large B-Cell Lymphoma (DLBCL), Phase 2 Trial, Phase 3 Trial, ROR1, Merck, waveLINE Program